At the time of writing, Aclaris Therapeutics Inc [ACRS] stock is trading at $3.80, down -12.04%. An important factor to consider is whether the stock is rising or falling in short-term value. The ACRS shares have gain 85.37% over the last week, with a monthly amount glided 194.57%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Aclaris Therapeutics Inc [NASDAQ: ACRS] stock has seen the most recent analyst activity on November 20, 2024, when Cantor Fitzgerald upgraded its rating to a Overweight. Previously, Leerink Partners upgraded its rating to Outperform on November 19, 2024, and elevated its price target to $7. On November 19, 2024, upgrade upgraded it’s rating to Buy and revised its price target to $7 on the stock. BTIG Research upgraded its rating to a Buy but stick to its price target of $8 on November 19, 2024. Piper Sandler upgraded its rating to a Overweight and raised its price target to $13 on November 18, 2024. H.C. Wainwright downgraded its rating to Neutral for this stock on January 22, 2024. In a note dated November 13, 2023, William Blair downgraded an Mkt Perform rating on this stock.
For the past year, the stock price of Aclaris Therapeutics Inc fluctuated between $0.77 and $5.17. Currently, Wall Street analysts expect the stock to reach $10.75 within the next 12 months. Aclaris Therapeutics Inc [NASDAQ: ACRS] shares were valued at $3.80 at the most recent close of the market. An investor can expect a potential return of 182.89% based on the average ACRS price forecast.
Analyzing the ACRS fundamentals
According to Aclaris Therapeutics Inc [NASDAQ:ACRS], the company’s sales were 27.08M for trailing twelve months, which represents an -53.18% plunge. Gross Profit Margin for this corporation currently stands at 0.54% with Operating Profit Margin at -1.5%, Pretax Profit Margin comes in at -1.38%, and Net Profit Margin reading is -1.37%. To continue investigating profitability, this company’s Return on Assets is posted at -0.2, Equity is -0.26 and Total Capital is -0.25.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.59 points at the first support level, and at 3.37 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.23, and for the 2nd resistance point, it is at 4.65.
Ratios To Look Out For
It is important to note that Aclaris Therapeutics Inc [NASDAQ:ACRS] has a current ratio of 7.03. On the other hand, the Quick Ratio is 7.03, and the Cash Ratio is 2.53. Considering the valuation of this stock, the price to sales ratio is 8.82, the price to book ratio is 2.09.
Transactions by insiders
Recent insider trading involved Mehra Anand, Director, that happened on Nov 19 ’24 when 0.67 million shares were purchased. 10% Owner, Leonard Braden Michael completed a deal on Aug 05 ’24 to buy 0.21 million shares. Meanwhile, 10% Owner Leonard Braden Michael bought 0.17 million shares on Aug 02 ’24.
